Pfizer thinking about consumer healthcare business sale
Pfizer’s consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.
Industry experts said it could fetch around four times sales, implying a potential value of up $14 billion.
Pfizer, which saw its shares rise about 1 percent at $36.50 in premarket trading, said it would decide on the future of its consumer unit during 2018.
Reuters first reported last November that a divestment of the Pfizer consumer business was under consideration. ■